Cytokinetics (CYTK): CEO sold ~$168K
Robert I Blum, CEO at Cytokinetics, sold ~$168K of Cytokinetics shares.
- ~$168K
- Approx. value · 5,000 sh @ $33.55
- 398K
- Holds after · shares reported
- Traded
- Jul 1, 2025
- Filed
- Jul 2, 2025
What stands out in this filing
- The sale was 1.2% of the shares this insider held before it; the filing reports 398,108 shares afterwards.
- 5,000 shares at an average of $33.55 each, as reported on the form.
- Filing box checked: sold under a Rule 10b5-1 plan.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- May 5, 2025InsiderOfficer sold ~$147K of CYTK shares in the open market
- May 6, 2025InsiderOfficer sold ~$70K of CYTK shares in the open market
- May 15, 2025InsiderDirector sold ~$43K of CYTK shares in the open market
- May 16, 2025InsiderCEO sold ~$155K of CYTK shares in the open market
- May 20, 2025InsiderOfficer sold ~$64K of CYTK shares in the open market
- Jun 2, 2025InsiderCEO sold ~$156K of CYTK shares in the open market
- Jun 3, 2025InsiderOfficer sold ~$64K of CYTK shares in the open market
- Jun 5, 2025Insider · 2 peopleInsiders: 2 sales (~$394K)
- Jun 11, 2025CongressDisclosed purchase of CYTK — reported range $1,001 - $15,000
- Jun 16, 2025InsiderCEO sold ~$169K of CYTK shares in the open market
- Jun 17, 2025InsiderOfficer sold ~$66K of CYTK shares in the open market
- Jun 17, 2025CongressDisclosed sale of CYTK — reported range $1,001 - $15,000
- Jul 1, 2025 · this disclosureInsiderCEO sold ~$168K of CYTK shares in the open market
What came next
- Jul 8, 2025InsiderOfficer sold ~$68K of CYTK shares in the open market
- Jul 14, 2025InsiderCEO sold ~$191K of CYTK shares in the open market
- Jul 22, 2025InsiderOfficer sold ~$75K of CYTK shares in the open market
- Jul 29, 2025InsiderCEO sold ~$182K of CYTK shares in the open market
- Aug 5, 2025InsiderOfficer sold ~$73K of CYTK shares in the open market
- Aug 15, 2025InsiderCEO sold ~$192K of CYTK shares in the open market
- Aug 19, 2025InsiderOfficer sold ~$77K of CYTK shares in the open market
- Sep 2, 2025Insider · 3 peopleInsiders: 3 sales (~$686K)
- Sep 9, 2025InsiderOfficer sold ~$103K of CYTK shares in the open market
- Sep 15, 2025InsiderCEO sold ~$249K of CYTK shares in the open market
- Sep 16, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
- Sep 23, 2025InsiderOfficer sold ~$99K of CYTK shares in the open market
- Sep 30, 2025InsiderDirector sold ~$369K of CYTK shares in the open market
- Oct 6, 2025InsiderDirector sold ~$405K of CYTK shares in the open market
- Oct 7, 2025InsiderOfficer sold ~$121K of CYTK shares in the open market
- Oct 16, 2025InsiderCEO sold ~$300K of CYTK shares in the open market
- Oct 21, 2025InsiderOfficer sold ~$123K of CYTK shares in the open market
- Oct 27, 2025InsiderDirector sold ~$257K of CYTK shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Cytokinetics
For Cytokinetics, OQRO holds 26 insider filings (SEC Form 4 or Form 144) and 1 Congress trade report dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CYTK page.
Other recent filings by Robert I Blum, President & CEO
- SEC Form 4 at Cytokinetics (CYTK)Nov 19, 2026
- SEC Form 4 at Cytokinetics (CYTK)Nov 19, 2026
- SEC Form 4 at Cytokinetics (CYTK)Nov 19, 2026
- SEC Form 4 at Cytokinetics (CYTK)Nov 2, 2026
- SEC Form 4 at Cytokinetics (CYTK)Oct 13, 2026
The full history of Robert I Blum, President & CEO is on the profile page.
How this filing works
Explore the data
Common questions
Which Cytokinetics (CYTK) insider traded, and how much?
Robert I Blum, CEO at Cytokinetics, sold ~$168K of Cytokinetics shares. 5,000 shares at $33.55.
When did it happen, and when was it made public?
Traded: Jul 1, 2025. Filed: Jul 2, 2025. That is 1 day between the two dates.
What stands out in this filing?
The sale was 1.2% of the shares this insider held before it; the filing reports 398,108 shares afterwards. 5,000 shares at an average of $33.55 each, as reported on the form. Filing box checked: sold under a Rule 10b5-1 plan.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Cytokinetics recently?
For Cytokinetics, OQRO holds 26 insider filings (SEC Form 4 or Form 144) and 1 Congress trade report dated in the last 90 days. They are listed on the CYTK page.
Does this mean CYTK stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Cytokinetics
- SEC Form 4Nov 19, 2026
- SEC Form 4Nov 19, 2026
- SEC Form 4Nov 19, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
Everything OQRO holds on this company is on its CYTK page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
